VAD方案化疗联合血液净化治疗MMRN疗效及对血清Scr、BUA水平的影响

发布时间：2018-03-08 17:19

本文选题：多发性骨髓瘤肾病　切入点：血液净化　出处：《中国地方病防治杂志》2017年03期 　论文类型：期刊论文

【摘要】：目的探究VAD方案化疗联合血液净化治疗多发性骨髓瘤肾病(MMRN)疗效及对血清肌酐(Scr)、血尿酸(BUA)水平的影响。方法 68例多发性骨髓瘤肾病患者依据建档顺序分组,各34例。两组均予以常规治疗,于此基础上对照组仅采用VAD方案化疗,观察组采用VAD方案化疗联合血液净化治疗,治疗3个月,对比两组治疗前后Scr、BUA、血钙水平,并统计临床疗效、不良反应发生情况。结果两组治疗前Scr、BUA、血钙水平无差异(P0.05);治疗后观察组Scr、BUA、血钙水平均低于对照组(P0.05);总有效率76.47%(26/34)高于对照组52.94%(18/34)(P0.05);两组不良反应发生率无差异(P0.05)。结论多发性骨髓瘤肾病患者联合应用VAD方案化疗与血液净化治疗效果显著,可有效降低Scr、BUA水平,改善肾功能,安全性较高。
[Abstract]:Objective to investigate the efficacy of VAD regimen combined with blood purification in the treatment of multiple myeloma nephropathy (MMRN) and its effect on serum creatinine creatinine (creatinine) and serum uric acid (UAA) levels. Methods 68 patients with multiple myeloma nephropathy were divided into two groups according to the order of filing. 34 cases in each group were treated with routine therapy. The control group was treated with VAD regimen only, while the observation group was treated with VAD regimen combined with blood purification for 3 months. The levels of serum calcium and ScrBUAwere compared between the two groups before and after treatment. And count the clinical curative effect, Results there was no difference in serum calcium level between the two groups before treatment (P 0.05); after treatment, the level of serum calcium in the observation group was lower than that in the control group (P 0.05); the total effective rate was 76.47% 26 / 34) and the total effective rate was higher than that in the control group (52.94% 18 / 34 P 0.05). There was no difference in the incidence of adverse reactions between the two groups (P 0.05). The effect of combined chemotherapy with VAD regimen and blood purification was significant in patients with primary myeloma nephropathy. It can effectively reduce the level of Scr-Bua and improve renal function.
【作者单位】：牡丹江医学院附属红旗医院;
【基金】：牡丹江市科技局科学计划项目(编号G2014s0021)
【分类号】：R692;R733.3

【参考文献】